ABBV-319

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameABBV-319
Drug Alias NameABBV-319
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionGlucocorticoid receptor agonistsB-lymphocyte antigen CD19 modulators
TargetsGlucocorticoid receptorB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicDry Eye SyndromesLymphoma, Follicular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicDry Eye SyndromesLymphoma, Follicular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A